Key Points
- Director Emma Reeve sold 15,666 shares of PTC Therapeutics stock on October 30th for approximately $1.09 million, leading to a 70.15% decrease in her ownership.
- The company reported a net margin of 35.65% and achieved quarterly revenue of $178.88 million, surpassing analysts' expectations of $173.01 million.
- PTC Therapeutics has received mixed ratings from analysts, with an average consensus rating of "Moderate Buy" and a price target of $69.57.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Emma Reeve sold 15,666 shares of PTC Therapeutics stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $69.50, for a total transaction of $1,088,787.00. Following the transaction, the director directly owned 6,666 shares in the company, valued at approximately $463,287. This represents a 70.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Emma Reeve also recently made the following trade(s):
- On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.96, for a total transaction of $1,686,069.52.
- On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.
PTC Therapeutics Stock Up 0.3%
Shares of NASDAQ PTCT opened at $68.31 on Friday. The company's fifty day moving average is $61.23 and its 200-day moving average is $52.80. The stock has a market cap of $5.43 billion, a price-to-earnings ratio of 9.80 and a beta of 0.55. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $69.88.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.24. The company had revenue of $178.88 million for the quarter, compared to analysts' expectations of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.29) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.
Institutional Investors Weigh In On PTC Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP increased its stake in PTC Therapeutics by 545.5% in the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 551 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 320 shares during the last quarter. GAMMA Investing LLC increased its stake in PTC Therapeutics by 86.3% in the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 441 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in PTC Therapeutics by 247.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 814 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in PTC Therapeutics in the 1st quarter valued at $61,000.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on PTCT. Truist Financial lifted their price target on shares of PTC Therapeutics from $80.00 to $86.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Bank of America dropped their price objective on shares of PTC Therapeutics from $82.00 to $76.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Citigroup raised their price objective on shares of PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Wall Street Zen lowered shares of PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $63.00 price objective (up from $60.00) on shares of PTC Therapeutics in a report on Friday, August 8th. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $69.57.
View Our Latest Research Report on PTC Therapeutics
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
